- Ensysce Biosciences (ENSC, Financial) has received a U.S. patent for a novel opioid use disorder (OUD) treatment, PF9001.
- PF9001 leverages Ensysce's TAAP and MPAR technologies for abuse deterrence and overdose protection.
- Supported by the National Institute on Drug Abuse, the treatment shows reduced cardiotoxicity and once-daily dosing for improved adherence.
Ensysce Biosciences (ENSC), a clinical-stage pharmaceutical company, has announced the receipt of a U.S. Patent Notice of Allowance for its innovative opioid use disorder (OUD) treatment, PF9001. This patent, granted by the U.S. Patent and Trademark Office, covers both the composition of matter and method of use for enzyme-cleavable methadone prodrugs, reinforcing Ensysce's intellectual property portfolio in the lucrative OUD market.
PF9001 stands out by utilizing Ensysce's proprietary TAAP and MPAR technologies aimed at deterring abuse and providing overdose protection. These advancements mark a significant improvement over traditional methadone treatments, which are often limited by cardiac side effects, respiratory depression, and overdose risks. The novel drug design aims to reduce cardiotoxicity, providing a safer alternative with once-daily dosing for prolonged and predictable effects.
The development of PF9001 is supported by the National Institute on Drug Abuse (NIDA) under Award Number UG3DA050271, underscoring the scientific validity and importance of Ensysce's approach in addressing the ongoing opioid crisis. The patent's acquisition signifies a strategic step forward for Ensysce Biosciences, although significant clinical development remains before the potential commercialization of PF9001.
CEO Dr. Lynn Kirkpatrick emphasized that PF9001 is the culmination of years of research focused on delivering safer OUD treatments. This novel medication could potentially improve treatment adherence and outcomes for patients by offering more tolerable options than current therapies.
